Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4071045
Max Phase: Preclinical
Molecular Formula: C96H110N12O23S2
Molecular Weight: 1864.13
Molecule Type: Small molecule
Associated Items:
ID: ALA4071045
Max Phase: Preclinical
Molecular Formula: C96H110N12O23S2
Molecular Weight: 1864.13
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: NC(=O)[C@H](CCCCNC(=S)Nc1ccc(-c2c3ccc(=O)cc-3oc3cc(O)ccc23)c(C(=O)O)c1)NC(=O)CN1C[C@H](Cc2ccccc2)NC(=O)CN(C(=O)CCC(=O)O)C[C@H](CCC(=O)O)NC(=O)CN(C(=O)Cc2ccc3c(c2)OCO3)C[C@H](CCC(=O)O)NC(=O)CN(C(=O)CCC2CCCCC2)C[C@H](Cc2ccccc2)NC(=O)c2ccc(cc2)CSCCC1=O
Standard InChI: InChI=1S/C96H110N12O23S2/c97-93(125)76(18-10-11-40-98-96(132)103-65-25-30-72(75(46-65)95(127)128)92-73-31-28-70(109)47-78(73)131-79-48-71(110)29-32-74(79)92)104-84(114)56-107-51-68(42-60-14-6-2-7-15-60)101-83(113)54-105(86(116)35-38-91(123)124)49-66(26-36-89(119)120)99-82(112)55-108(88(118)45-63-21-33-77-80(44-63)130-58-129-77)50-67(27-37-90(121)122)100-81(111)53-106(85(115)34-22-59-12-4-1-5-13-59)52-69(43-61-16-8-3-9-17-61)102-94(126)64-23-19-62(20-24-64)57-133-41-39-87(107)117/h2-3,6-9,14-17,19-21,23-25,28-33,44,46-48,59,66-69,76,109H,1,4-5,10-13,18,22,26-27,34-43,45,49-58H2,(H2,97,125)(H,99,112)(H,100,111)(H,101,113)(H,102,126)(H,104,114)(H,119,120)(H,121,122)(H,123,124)(H,127,128)(H2,98,103,132)/t66-,67-,68-,69-,76-/m0/s1
Standard InChI Key: ANZRNHPEVLXURS-BHFRBWONSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1864.13 | Molecular Weight (Monoisotopic): 1862.7248 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Shi Y, Challa S, Sang P, She F, Li C, Gray GM, Nimmagadda A, Teng P, Odom T, Wang Y, van der Vaart A, Li Q, Cai J.. (2017) One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2., 60 (22): [PMID:29111705] [10.1021/acs.jmedchem.7b01280] |
Source(1):